Article
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2010
Sekeres Mikkael A, List Alan F, Cuthbertson David, Paquette Ronald, Ganetzky Rebecca, Ganetsky Rebecca, Latham Deborah, Paulic Katarina, Afable Manuel, Saba Hussain I, Loughran Thomas P, Maciejewski Jaroslaw P
Abstract excerpt
PURPOSE: Lenalidomide and azacitidine are active in patients with lower- and higher-risk myelodysplastic syndromes (MDS). These agents may complement each other by targeting both the bone marrow microenvironment and hypomethylating action on the malignant clone. PATIENTS AND METHODS: This phase I trial explored the safety of combination therapy in patients with higher-risk MDS. Response and characterization of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.